Previous 10 | Next 10 |
The following slide deck was published by Invitae Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Invitae Corporation 2022 Q2 - Results - Earnings Call Presentation
Invitae Corp (NVTA) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 ET Company Participants Hoki Luk - Head, IR Kenneth Knight - President, CEO & Director Roxi Wen - CFO Conference Call Participants Yuko Oku - Morgan Stanley Puneet Sou...
Invitae ( NYSE: NVTA ) has reaffirmed its 2022 financial guidance as the medical genetics company's Q2 2022 results beat on both the top and bottom lines . Invitae ( NVTA ), however, swung to a quarterly loss of ~$2.5B (-$10.87 per share, diluted) from net income o...
Invitae press release ( NYSE: NVTA ): Q2 Non-GAAP EPS of -$0.68 beats by $0.08 . Revenue of $136.6M (+17.4% Y/Y) beats by $0.55M . GAAP gross margin was 19.2%. Non-GAAP gross margin was 40.1% as compared with 36.6% in the first quarter of 2022 and 35.4% in the ...
New NCCN Colorectal Cancer Guidelines Recommend Genetic Testing for All Diagnosed Patients PR Newswire - Significant changes made to current NCCN testing recommendations increase access to testing for historically underserved populations - SAN FRANCISCO ,...
Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 PR Newswire SAN FRANCISCO , Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter ...
These days, Invitae Corporation (NYSE: NVTA) just can't catch a break. On Tuesday, the company was slammed with yet another analyst downgrade, and as a result, its stock ended up falling by more than 13% over the week, data compiled by S&P Global Market Intelligence reveal. ...
Cowen has downgraded Invitae ( NYSE: NVTA ) to market perform from outperform following uncertainty related to debt refinancing. The firm also trimmed its price target to $2.5 from $8 (~17% upside based on Monday's close). Shares are down 9% in Tuesday morning trad...
Invitae ( NYSE: NVTA ) stock was in the green ( +4% ) on July 21, despite Raymond James downgrading the shares to Market Perform from Outperform. Earlier in the day, healthcare services stocks got a boost amid Amazon's announcement that it was acquiring One Me...
Shares of Invitae (NYSE: NVTA) were crashing 15.4% lower as of 3:16 p.m. ET on Tuesday. The steep decline came after the medical genetics company announced several developments on Monday that rattled investors. Invitae revealed a shakeup in its executive ranks. CEO Sean George h...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...